Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2026)

Neuroone Medical Technologies has disclosed Cash & Equivalents across 10 years of filings, most recently posting $2.8 million for Q1 2026.

• Quarterly Cash & Equivalents rose 115.38% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 115.38% YoY) and the FY2025 annual result came in at $6.6 million, up 350.01% from the prior year.
• Cash & Equivalents retreated to $2.8 million in Q1 2026, from $3.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $12.9 million in Q1 2022 and bottomed at $1.1 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $3.6 million (2025), against an average of $4.7 million.
• Year-over-year, Cash & Equivalents slumped 72.57% in 2024 and surged 393.83% in 2025.
• Neuroone Medical Technologies' Cash & Equivalents stood at $4.7 million in 2022, then slumped by 42.56% to $2.7 million in 2023, then sank by 57.69% to $1.1 million in 2024, then surged by 217.36% to $3.6 million in 2025, then retreated by 22.22% to $2.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.8 million, $3.6 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.